Breast Cancer

Key clinical point: Presence of reproductive tract infections had a protective effect against the development of breast cancer (BC) and was associated with a better prognosis in patients with BC.

Major finding: Reproductive tract infections were associated with a lower risk for BC (odds ratio [OR] 0.80; 95% CI 0.65-0.98). Patients with reproductive vs non-reproductive tract infections showed improved overall survival (hazard ratio [HR] 0.61; 95% CI 0.40-0.94), whereas the risk for disease progression was lower in women with reproductive tract infections and >327 vs ≤327 menstrual cycles (HR 0.52; 95% CI 0.34-0.79).

Study details: Findings are from a case-control study including 1003 patients with BC and 1107 cancer-free control individuals and a cohort study including 4264 patients with BC, of which 685 women had a history of reproductive tract infections.

Disclosures: This study was funded by the National Natural Science Foundation of China and Science and Technology Planning Project of Guangdong Province. The authors declared no conflicts of interest.

Source: Li Y et al. Interaction of reproductive tract infections with estrogen exposure on breast cancer risk and prognosis. BMC Womens Health. 2023;23:238 (May 8). Doi: 10.1186/s12905-023-02383-3

Key clinical point: Presence of reproductive tract infections had a protective effect against the development of breast cancer (BC) and was associated with a better prognosis in patients with BC.

Major finding: Reproductive tract infections were associated with a lower risk for BC (odds ratio [OR] 0.80; 95% CI 0.65-0.98). Patients with reproductive vs non-reproductive tract infections showed improved overall survival (hazard ratio [HR] 0.61; 95% CI 0.40-0.94), whereas the risk for disease progression was lower in women with reproductive tract infections and >327 vs ≤327 menstrual cycles (HR 0.52; 95% CI 0.34-0.79).

Study details: Findings are from a case-control study including 1003 patients with BC and 1107 cancer-free control individuals and a cohort study including 4264 patients with BC, of which 685 women had a history of reproductive tract infections.

Disclosures: This study was funded by the National Natural Science Foundation of China and Science and Technology Planning Project of Guangdong Province. The authors declared no conflicts of interest.

Source: Li Y et al. Interaction of reproductive tract infections with estrogen exposure on breast cancer risk and prognosis. BMC Womens Health. 2023;23:238 (May 8). Doi: 10.1186/s12905-023-02383-3

Key clinical point: Presence of reproductive tract infections had a protective effect against the development of breast cancer (BC) and was associated with a better prognosis in patients with BC.

Major finding: Reproductive tract infections were associated with a lower risk for BC (odds ratio [OR] 0.80; 95% CI 0.65-0.98). Patients with reproductive vs non-reproductive tract infections showed improved overall survival (hazard ratio [HR] 0.61; 95% CI 0.40-0.94), whereas the risk for disease progression was lower in women with reproductive tract infections and >327 vs ≤327 menstrual cycles (HR 0.52; 95% CI 0.34-0.79).

Study details: Findings are from a case-control study including 1003 patients with BC and 1107 cancer-free control individuals and a cohort study including 4264 patients with BC, of which 685 women had a history of reproductive tract infections.

Disclosures: This study was funded by the National Natural Science Foundation of China and Science and Technology Planning Project of Guangdong Province. The authors declared no conflicts of interest.

Source: Li Y et al. Interaction of reproductive tract infections with estrogen exposure on breast cancer risk and prognosis. BMC Womens Health. 2023;23:238 (May 8). Doi: 10.1186/s12905-023-02383-3

Key clinical point: Female breast cancer (BC) survivors are at a higher risk of experiencing sexual dysfunction symptoms compared with women from the general population.

Major finding: The risk for sexual dysfunction was higher in female BC survivors compared with women from the general population (hazard ratio [HR] 1.60; 95% CI 1.51-1.70), with the risk being more prominent within the first 5 years after BC diagnosis (HR 2.05; 95% CI 1.89-2.22) and in women who were <50 years old at the time of BC diagnosis (HR 3.05; 95% CI 2.65-3.51).

Study details: Findings are from the Utah Population Database cohort study including 19,709 women age ≥18 years who had survived BC and 93,389 age- and birth state-matched women from the general population.

Disclosures: This study was supported by grants from the US National Institutes of Health and other sources. The authors declared no conflicts of interest.

Source: Chang CP et al. Breast cancer survivorship and sexual dysfunction: A population-based cohort study. Breast Cancer Res Treat. 2023 (May 9). Doi: 10.1007/s10549-023-06953-9

Key clinical point: Female breast cancer (BC) survivors are at a higher risk of experiencing sexual dysfunction symptoms compared with women from the general population.

Major finding: The risk for sexual dysfunction was higher in female BC survivors compared with women from the general population (hazard ratio [HR] 1.60; 95% CI 1.51-1.70), with the risk being more prominent within the first 5 years after BC diagnosis (HR 2.05; 95% CI 1.89-2.22) and in women who were <50 years old at the time of BC diagnosis (HR 3.05; 95% CI 2.65-3.51).

Study details: Findings are from the Utah Population Database cohort study including 19,709 women age ≥18 years who had survived BC and 93,389 age- and birth state-matched women from the general population.

Disclosures: This study was supported by grants from the US National Institutes of Health and other sources. The authors declared no conflicts of interest.

Source: Chang CP et al. Breast cancer survivorship and sexual dysfunction: A population-based cohort study. Breast Cancer Res Treat. 2023 (May 9). Doi: 10.1007/s10549-023-06953-9

Key clinical point: Female breast cancer (BC) survivors are at a higher risk of experiencing sexual dysfunction symptoms compared with women from the general population.

Major finding: The risk for sexual dysfunction was higher in female BC survivors compared with women from the general population (hazard ratio [HR] 1.60; 95% CI 1.51-1.70), with the risk being more prominent within the first 5 years after BC diagnosis (HR 2.05; 95% CI 1.89-2.22) and in women who were <50 years old at the time of BC diagnosis (HR 3.05; 95% CI 2.65-3.51).

Study details: Findings are from the Utah Population Database cohort study including 19,709 women age ≥18 years who had survived BC and 93,389 age- and birth state-matched women from the general population.

Disclosures: This study was supported by grants from the US National Institutes of Health and other sources. The authors declared no conflicts of interest.

Source: Chang CP et al. Breast cancer survivorship and sexual dysfunction: A population-based cohort study. Breast Cancer Res Treat. 2023 (May 9). Doi: 10.1007/s10549-023-06953-9

Key clinical point: Some relatives of women with early-onset breast cancer (BC) may have an increased risk of developing discordant early-onset cancers (other than breast cancers).

Major finding: Among relatives of women with early-onset BC, offspring had a higher risk for any discordant early-onset cancer (standardized incidence ratio [SIR] 1.27; 95% CI 1.03-1.55), siblings' children had an increased risk for early-onset testicular cancer (SIR 1.74; 95% CI 1.07-2.69) and ovarian cancer (SIR 2.69; 95% CI 1.08-5.53), and siblings had an increased risk for early-onset pancreatic cancer (SIR 7.61; 95% CI 1.57-22.23).

Study details: Findings are from an analysis of a population-based cohort including 54,753 relatives from 5562 families of females diagnosed with early-onset BC.

Disclosures: This study was funded by the Cancer Foundation Finland and Academy of Finland. The authors declared no conflicts of interest.

Source: Rantala JNJ et al. Familial aggregation of early-onset cancers in early-onset breast cancer families. Int J Cancer. 2023;153(2):331-340 (Apr 19). Doi: 10.1002/ijc.34538

Key clinical point: Some relatives of women with early-onset breast cancer (BC) may have an increased risk of developing discordant early-onset cancers (other than breast cancers).

Major finding: Among relatives of women with early-onset BC, offspring had a higher risk for any discordant early-onset cancer (standardized incidence ratio [SIR] 1.27; 95% CI 1.03-1.55), siblings' children had an increased risk for early-onset testicular cancer (SIR 1.74; 95% CI 1.07-2.69) and ovarian cancer (SIR 2.69; 95% CI 1.08-5.53), and siblings had an increased risk for early-onset pancreatic cancer (SIR 7.61; 95% CI 1.57-22.23).

Study details: Findings are from an analysis of a population-based cohort including 54,753 relatives from 5562 families of females diagnosed with early-onset BC.

Disclosures: This study was funded by the Cancer Foundation Finland and Academy of Finland. The authors declared no conflicts of interest.

Source: Rantala JNJ et al. Familial aggregation of early-onset cancers in early-onset breast cancer families. Int J Cancer. 2023;153(2):331-340 (Apr 19). Doi: 10.1002/ijc.34538

Key clinical point: Some relatives of women with early-onset breast cancer (BC) may have an increased risk of developing discordant early-onset cancers (other than breast cancers).

Major finding: Among relatives of women with early-onset BC, offspring had a higher risk for any discordant early-onset cancer (standardized incidence ratio [SIR] 1.27; 95% CI 1.03-1.55), siblings' children had an increased risk for early-onset testicular cancer (SIR 1.74; 95% CI 1.07-2.69) and ovarian cancer (SIR 2.69; 95% CI 1.08-5.53), and siblings had an increased risk for early-onset pancreatic cancer (SIR 7.61; 95% CI 1.57-22.23).

Study details: Findings are from an analysis of a population-based cohort including 54,753 relatives from 5562 families of females diagnosed with early-onset BC.

Disclosures: This study was funded by the Cancer Foundation Finland and Academy of Finland. The authors declared no conflicts of interest.

Source: Rantala JNJ et al. Familial aggregation of early-onset cancers in early-onset breast cancer families. Int J Cancer. 2023;153(2):331-340 (Apr 19). Doi: 10.1002/ijc.34538

Key clinical point: Anlotinib combined with chemotherapy demonstrated good activity in the treatment of metastatic triple-negative breast cancer (TNBC) along with an acceptable safety profile in a single-arm phase 2 study.

Major finding: The median progression-free survival was 8.8 months (95% CI 6.5-11.1 months), and the median overall survival was 19.0 months (95% CI 12.1-25.9 months). Grade 3-4 treatment-related adverse events (TRAE) included neutropenia (22.5%), leukopenia (20.0%), secondary hypertension (10.0%), hand-foot syndrome (5.0%), vomiting (5.0%), proteinuria (5.0%), and thrombocytopenia (2.5%), and no deaths due to TRAE were reported.

Study details: Findings are from a prospective phase 2 trial including 40 patients with metastatic TNBC who were previously treated with anthracycline or taxane and received anlotinib combined with chemotherapy.

Disclosures: This study received funding support from the Shenzhen Basic Research Program, China, and the National Natural Science Foundation of China. The authors declared no conflicts of interest.

Source: Huang JY et al. A single-arm phase II clinical trial of anlotinib combined with chemotherapy for the treatment of metastatic triple-negative breast cancer. Front Oncol. 2023;13:1122294 (Apr 12). Doi: 10.3389/fonc.2023.1122294

Key clinical point: Anlotinib combined with chemotherapy demonstrated good activity in the treatment of metastatic triple-negative breast cancer (TNBC) along with an acceptable safety profile in a single-arm phase 2 study.

Major finding: The median progression-free survival was 8.8 months (95% CI 6.5-11.1 months), and the median overall survival was 19.0 months (95% CI 12.1-25.9 months). Grade 3-4 treatment-related adverse events (TRAE) included neutropenia (22.5%), leukopenia (20.0%), secondary hypertension (10.0%), hand-foot syndrome (5.0%), vomiting (5.0%), proteinuria (5.0%), and thrombocytopenia (2.5%), and no deaths due to TRAE were reported.

Study details: Findings are from a prospective phase 2 trial including 40 patients with metastatic TNBC who were previously treated with anthracycline or taxane and received anlotinib combined with chemotherapy.

Disclosures: This study received funding support from the Shenzhen Basic Research Program, China, and the National Natural Science Foundation of China. The authors declared no conflicts of interest.

Source: Huang JY et al. A single-arm phase II clinical trial of anlotinib combined with chemotherapy for the treatment of metastatic triple-negative breast cancer. Front Oncol. 2023;13:1122294 (Apr 12). Doi: 10.3389/fonc.2023.1122294

Key clinical point: Anlotinib combined with chemotherapy demonstrated good activity in the treatment of metastatic triple-negative breast cancer (TNBC) along with an acceptable safety profile in a single-arm phase 2 study.

Major finding: The median progression-free survival was 8.8 months (95% CI 6.5-11.1 months), and the median overall survival was 19.0 months (95% CI 12.1-25.9 months). Grade 3-4 treatment-related adverse events (TRAE) included neutropenia (22.5%), leukopenia (20.0%), secondary hypertension (10.0%), hand-foot syndrome (5.0%), vomiting (5.0%), proteinuria (5.0%), and thrombocytopenia (2.5%), and no deaths due to TRAE were reported.

Study details: Findings are from a prospective phase 2 trial including 40 patients with metastatic TNBC who were previously treated with anthracycline or taxane and received anlotinib combined with chemotherapy.

Disclosures: This study received funding support from the Shenzhen Basic Research Program, China, and the National Natural Science Foundation of China. The authors declared no conflicts of interest.

Source: Huang JY et al. A single-arm phase II clinical trial of anlotinib combined with chemotherapy for the treatment of metastatic triple-negative breast cancer. Front Oncol. 2023;13:1122294 (Apr 12). Doi: 10.3389/fonc.2023.1122294

Key clinical point: Targeted axillary dissection (TAD) by marking the metastatic lymph node with ¹²⁵I seeds before neoadjuvant chemotherapy (NACT) showed excellent identification rates and ruled out the need for remarking before surgery.

Major finding: The identification rates of the marked lymph node (MLN) and sentinel node (SN) were 99.3% and 91.5%, respectively, with the TAD procedure being successful in 91.5% of patients based on the identification of both MLN and SN. Overall, 40.8% of patients achieved axillary pathologic complete response and could be spared from surgery.

Study details: Findings are from a cohort study including 142 patients with BC who underwent TAD after ¹²⁵I seeds were placed before NACT.

Disclosures: This study was funded by Helsefonden. The authors did not report conflicts of interest.

Source: Munck F et al. Targeted axillary dissection with ¹²⁵I seed placement before neoadjuvant chemotherapy in a Danish multicenter cohort. Ann Surg Oncol. 2023 (Apr 16). Doi: 10.1245/s10434-023-13432-4

Key clinical point: Targeted axillary dissection (TAD) by marking the metastatic lymph node with ¹²⁵I seeds before neoadjuvant chemotherapy (NACT) showed excellent identification rates and ruled out the need for remarking before surgery.

Major finding: The identification rates of the marked lymph node (MLN) and sentinel node (SN) were 99.3% and 91.5%, respectively, with the TAD procedure being successful in 91.5% of patients based on the identification of both MLN and SN. Overall, 40.8% of patients achieved axillary pathologic complete response and could be spared from surgery.

Study details: Findings are from a cohort study including 142 patients with BC who underwent TAD after ¹²⁵I seeds were placed before NACT.

Disclosures: This study was funded by Helsefonden. The authors did not report conflicts of interest.

Source: Munck F et al. Targeted axillary dissection with ¹²⁵I seed placement before neoadjuvant chemotherapy in a Danish multicenter cohort. Ann Surg Oncol. 2023 (Apr 16). Doi: 10.1245/s10434-023-13432-4

Key clinical point: Targeted axillary dissection (TAD) by marking the metastatic lymph node with ¹²⁵I seeds before neoadjuvant chemotherapy (NACT) showed excellent identification rates and ruled out the need for remarking before surgery.

Major finding: The identification rates of the marked lymph node (MLN) and sentinel node (SN) were 99.3% and 91.5%, respectively, with the TAD procedure being successful in 91.5% of patients based on the identification of both MLN and SN. Overall, 40.8% of patients achieved axillary pathologic complete response and could be spared from surgery.

Study details: Findings are from a cohort study including 142 patients with BC who underwent TAD after ¹²⁵I seeds were placed before NACT.

Disclosures: This study was funded by Helsefonden. The authors did not report conflicts of interest.

Source: Munck F et al. Targeted axillary dissection with ¹²⁵I seed placement before neoadjuvant chemotherapy in a Danish multicenter cohort. Ann Surg Oncol. 2023 (Apr 16). Doi: 10.1245/s10434-023-13432-4

Key clinical point: Pretreatment tumor stage and nodal involvement could predict the risk for disease relapse in patients with human epidermal growth factor receptor 2-positive (HER2+) early breast cancer (BC) who had achieved pathologic complete response (pCR) with neoadjuvant chemotherapy plus anti-HER2 therapy.

Major finding: Patients who did vs did not achieve pCR had prolonged event-free survival (EFS; hazard ratio [HR] 0.39) and overall survival (HR 0.32; both P < .001). However, in patients with pCR, higher pretreatment tumor stage (cT3-4 vs cT1-2; P = .007) and presence of nodal involvement (cN+ vs cN−; P = .039) could worsen EFS.

Study details: This study analyzed the data of 3710 patients with HER2+ early BC from 11 trials who had received neoadjuvant chemotherapy+anti-HER2 therapy, of which 40.4% of patients had achieved pCR.

Disclosures: This study was supported by author Sibylle Loibl. Several authors declared serving as consultants or advisors, receiving honoraria or research funding, or having other ties with various sources.

Source: van Mackelenbergh MT et al on behalf of the CTNeoBC project. Pathologic complete response and individual patient prognosis after neoadjuvant chemotherapy plus anti-human epidermal growth factor receptor 2 therapy of human epidermal growth factor receptor 2-positive early breast cancer. J Clin Oncol. 2023 (Apr 19). Doi: 10.1200/JCO.22.02241

Key clinical point: Pretreatment tumor stage and nodal involvement could predict the risk for disease relapse in patients with human epidermal growth factor receptor 2-positive (HER2+) early breast cancer (BC) who had achieved pathologic complete response (pCR) with neoadjuvant chemotherapy plus anti-HER2 therapy.

Major finding: Patients who did vs did not achieve pCR had prolonged event-free survival (EFS; hazard ratio [HR] 0.39) and overall survival (HR 0.32; both P < .001). However, in patients with pCR, higher pretreatment tumor stage (cT3-4 vs cT1-2; P = .007) and presence of nodal involvement (cN+ vs cN−; P = .039) could worsen EFS.

Study details: This study analyzed the data of 3710 patients with HER2+ early BC from 11 trials who had received neoadjuvant chemotherapy+anti-HER2 therapy, of which 40.4% of patients had achieved pCR.

Disclosures: This study was supported by author Sibylle Loibl. Several authors declared serving as consultants or advisors, receiving honoraria or research funding, or having other ties with various sources.

Source: van Mackelenbergh MT et al on behalf of the CTNeoBC project. Pathologic complete response and individual patient prognosis after neoadjuvant chemotherapy plus anti-human epidermal growth factor receptor 2 therapy of human epidermal growth factor receptor 2-positive early breast cancer. J Clin Oncol. 2023 (Apr 19). Doi: 10.1200/JCO.22.02241

Key clinical point: Pretreatment tumor stage and nodal involvement could predict the risk for disease relapse in patients with human epidermal growth factor receptor 2-positive (HER2+) early breast cancer (BC) who had achieved pathologic complete response (pCR) with neoadjuvant chemotherapy plus anti-HER2 therapy.

Major finding: Patients who did vs did not achieve pCR had prolonged event-free survival (EFS; hazard ratio [HR] 0.39) and overall survival (HR 0.32; both P < .001). However, in patients with pCR, higher pretreatment tumor stage (cT3-4 vs cT1-2; P = .007) and presence of nodal involvement (cN+ vs cN−; P = .039) could worsen EFS.

Study details: This study analyzed the data of 3710 patients with HER2+ early BC from 11 trials who had received neoadjuvant chemotherapy+anti-HER2 therapy, of which 40.4% of patients had achieved pCR.

Disclosures: This study was supported by author Sibylle Loibl. Several authors declared serving as consultants or advisors, receiving honoraria or research funding, or having other ties with various sources.

Source: van Mackelenbergh MT et al on behalf of the CTNeoBC project. Pathologic complete response and individual patient prognosis after neoadjuvant chemotherapy plus anti-human epidermal growth factor receptor 2 therapy of human epidermal growth factor receptor 2-positive early breast cancer. J Clin Oncol. 2023 (Apr 19). Doi: 10.1200/JCO.22.02241

Key clinical point: The incidence rate of squamous cell carcinoma (SCC) was extremely low and, hence, of minimal public health concern in patients with non-SCC breast cancer (BC) or carcinoma in situ who underwent implant-based reconstruction.

Major finding: Only 1 woman was diagnosed with SCC after 52 months of BC diagnosis. The incidence rate of SCC after implant-based reconstruction was extremely low (2.37 per million person-years) and was not significantly higher in women with BC than in the general population (standardized incidence ratio 2.33; 95% CI 0.06-13.0).

Study details: Findings are from a cohort study including 56,785 women with BC or carcinoma in situ who underwent cancer-directed mastectomy with implant reconstruction.

Disclosures: This study was supported by the US National Cancer Institute. Some authors declared receiving personal fees or grants or having other ties with several sources.

Source: Kinslow CJ et al. Risk of squamous cell carcinoma of the breast following postmastectomy implant reconstruction in women with breast cancer and carcinoma in situ. JAMA Surg. 2023 (Apr 19). Doi: 10.1001/jamasurg.2023.0262 

Key clinical point: The incidence rate of squamous cell carcinoma (SCC) was extremely low and, hence, of minimal public health concern in patients with non-SCC breast cancer (BC) or carcinoma in situ who underwent implant-based reconstruction.

Major finding: Only 1 woman was diagnosed with SCC after 52 months of BC diagnosis. The incidence rate of SCC after implant-based reconstruction was extremely low (2.37 per million person-years) and was not significantly higher in women with BC than in the general population (standardized incidence ratio 2.33; 95% CI 0.06-13.0).

Study details: Findings are from a cohort study including 56,785 women with BC or carcinoma in situ who underwent cancer-directed mastectomy with implant reconstruction.

Disclosures: This study was supported by the US National Cancer Institute. Some authors declared receiving personal fees or grants or having other ties with several sources.

Source: Kinslow CJ et al. Risk of squamous cell carcinoma of the breast following postmastectomy implant reconstruction in women with breast cancer and carcinoma in situ. JAMA Surg. 2023 (Apr 19). Doi: 10.1001/jamasurg.2023.0262 

Key clinical point: The incidence rate of squamous cell carcinoma (SCC) was extremely low and, hence, of minimal public health concern in patients with non-SCC breast cancer (BC) or carcinoma in situ who underwent implant-based reconstruction.

Major finding: Only 1 woman was diagnosed with SCC after 52 months of BC diagnosis. The incidence rate of SCC after implant-based reconstruction was extremely low (2.37 per million person-years) and was not significantly higher in women with BC than in the general population (standardized incidence ratio 2.33; 95% CI 0.06-13.0).

Study details: Findings are from a cohort study including 56,785 women with BC or carcinoma in situ who underwent cancer-directed mastectomy with implant reconstruction.

Disclosures: This study was supported by the US National Cancer Institute. Some authors declared receiving personal fees or grants or having other ties with several sources.

Source: Kinslow CJ et al. Risk of squamous cell carcinoma of the breast following postmastectomy implant reconstruction in women with breast cancer and carcinoma in situ. JAMA Surg. 2023 (Apr 19). Doi: 10.1001/jamasurg.2023.0262 

Key clinical point: Adherence to the American Institute for Cancer Research and American Cancer Society’s lifestyle recommendations reduced the risk for disease recurrence and improved mortality in patients with high-risk breast cancer (BC).

Major finding: Patients in the highest vs lowest tertile of lifestyle index scores (LIS) experienced a 37% reduction in recurrence (hazard ratio [HR] 0.63; 95% CI 0.48-0.82) and those in the middle (HR 0.70; P = .03) and highest (HR 0.42; P < .001) vs lowest tertile of LIS had significant reductions in mortality.

Study details: Findings are from the prospective, observational, DELCaP (The Diet, Exercise, Lifestyles, and Cancer Prognosis) study including 1340 chemotherapy-naive women with high-risk stage I to III BC, of which the majority (65.3%) of women had hormone receptor-positive BC.

Disclosures: This study was supported by the US National Cancer Institute and The Breast Cancer Research Foundation, New York Some authors declared serving as members of independent data monitoring committees or receiving grants or personal fees from several sources.

Source: Cannioto RA et al. Adherence to cancer prevention lifestyle recommendations before, during, and 2 years after treatment for high-risk breast cancer. JAMA Netw Open. 2023;6(5):e2311673 (May 4). Doi: 10.1001/jamanetworkopen.2023.11673

Key clinical point: Adherence to the American Institute for Cancer Research and American Cancer Society’s lifestyle recommendations reduced the risk for disease recurrence and improved mortality in patients with high-risk breast cancer (BC).

Major finding: Patients in the highest vs lowest tertile of lifestyle index scores (LIS) experienced a 37% reduction in recurrence (hazard ratio [HR] 0.63; 95% CI 0.48-0.82) and those in the middle (HR 0.70; P = .03) and highest (HR 0.42; P < .001) vs lowest tertile of LIS had significant reductions in mortality.

Study details: Findings are from the prospective, observational, DELCaP (The Diet, Exercise, Lifestyles, and Cancer Prognosis) study including 1340 chemotherapy-naive women with high-risk stage I to III BC, of which the majority (65.3%) of women had hormone receptor-positive BC.

Disclosures: This study was supported by the US National Cancer Institute and The Breast Cancer Research Foundation, New York Some authors declared serving as members of independent data monitoring committees or receiving grants or personal fees from several sources.

Source: Cannioto RA et al. Adherence to cancer prevention lifestyle recommendations before, during, and 2 years after treatment for high-risk breast cancer. JAMA Netw Open. 2023;6(5):e2311673 (May 4). Doi: 10.1001/jamanetworkopen.2023.11673

Key clinical point: Adherence to the American Institute for Cancer Research and American Cancer Society’s lifestyle recommendations reduced the risk for disease recurrence and improved mortality in patients with high-risk breast cancer (BC).

Major finding: Patients in the highest vs lowest tertile of lifestyle index scores (LIS) experienced a 37% reduction in recurrence (hazard ratio [HR] 0.63; 95% CI 0.48-0.82) and those in the middle (HR 0.70; P = .03) and highest (HR 0.42; P < .001) vs lowest tertile of LIS had significant reductions in mortality.

Study details: Findings are from the prospective, observational, DELCaP (The Diet, Exercise, Lifestyles, and Cancer Prognosis) study including 1340 chemotherapy-naive women with high-risk stage I to III BC, of which the majority (65.3%) of women had hormone receptor-positive BC.

Disclosures: This study was supported by the US National Cancer Institute and The Breast Cancer Research Foundation, New York Some authors declared serving as members of independent data monitoring committees or receiving grants or personal fees from several sources.

Source: Cannioto RA et al. Adherence to cancer prevention lifestyle recommendations before, during, and 2 years after treatment for high-risk breast cancer. JAMA Netw Open. 2023;6(5):e2311673 (May 4). Doi: 10.1001/jamanetworkopen.2023.11673

Key clinical point: Breast cancer (BC) recurrence rates are lower among patients treated with the combination of anthracycline and taxane compared with a taxane regimen without anthracycline or an anthracycline-based regimen without taxane.

Major finding: Anthracycline plus taxane reduced the rate of BC recurrence by 14% (rate ratio [RR] 0.86; P = .0004) compared with taxane only and by 13% (RR 0.87; P < .0001) compared with anthracycline only. The highest benefit was observed among patients receiving anthracycline concurrently with docetaxel+cyclophosphamide vs docetaxel+cyclophosphamide only (RR 0.58; P < .0001).

Study details: Findings are from a meta-analysis including more than 100,000 women with early-stage BC from 86 trials on anthracycline- and taxane-based chemotherapies.

Disclosures: This study is funded by Cancer Research UK. The authors declared receiving grants, payments, honoraria, consulting fees, or travel support from or having other ties with various sources.

Source: Early Breast Cancer Trialists' Collaborative Group. Anthracycline-containing and taxane-containing chemotherapy for early-stage operable breast cancer: A patient-level meta-analysis of 100 000 women from 86 randomised trials. Lancet. 2023;401(10384):1277-1292 (Apr 15). Doi: 10.1016/S0140-6736(23)00285-4

Key clinical point: Breast cancer (BC) recurrence rates are lower among patients treated with the combination of anthracycline and taxane compared with a taxane regimen without anthracycline or an anthracycline-based regimen without taxane.

Major finding: Anthracycline plus taxane reduced the rate of BC recurrence by 14% (rate ratio [RR] 0.86; P = .0004) compared with taxane only and by 13% (RR 0.87; P < .0001) compared with anthracycline only. The highest benefit was observed among patients receiving anthracycline concurrently with docetaxel+cyclophosphamide vs docetaxel+cyclophosphamide only (RR 0.58; P < .0001).

Study details: Findings are from a meta-analysis including more than 100,000 women with early-stage BC from 86 trials on anthracycline- and taxane-based chemotherapies.

Disclosures: This study is funded by Cancer Research UK. The authors declared receiving grants, payments, honoraria, consulting fees, or travel support from or having other ties with various sources.

Source: Early Breast Cancer Trialists' Collaborative Group. Anthracycline-containing and taxane-containing chemotherapy for early-stage operable breast cancer: A patient-level meta-analysis of 100 000 women from 86 randomised trials. Lancet. 2023;401(10384):1277-1292 (Apr 15). Doi: 10.1016/S0140-6736(23)00285-4

Key clinical point: Breast cancer (BC) recurrence rates are lower among patients treated with the combination of anthracycline and taxane compared with a taxane regimen without anthracycline or an anthracycline-based regimen without taxane.

Major finding: Anthracycline plus taxane reduced the rate of BC recurrence by 14% (rate ratio [RR] 0.86; P = .0004) compared with taxane only and by 13% (RR 0.87; P < .0001) compared with anthracycline only. The highest benefit was observed among patients receiving anthracycline concurrently with docetaxel+cyclophosphamide vs docetaxel+cyclophosphamide only (RR 0.58; P < .0001).

Study details: Findings are from a meta-analysis including more than 100,000 women with early-stage BC from 86 trials on anthracycline- and taxane-based chemotherapies.

Disclosures: This study is funded by Cancer Research UK. The authors declared receiving grants, payments, honoraria, consulting fees, or travel support from or having other ties with various sources.

Source: Early Breast Cancer Trialists' Collaborative Group. Anthracycline-containing and taxane-containing chemotherapy for early-stage operable breast cancer: A patient-level meta-analysis of 100 000 women from 86 randomised trials. Lancet. 2023;401(10384):1277-1292 (Apr 15). Doi: 10.1016/S0140-6736(23)00285-4

Key clinical point: Temporarily discontinuing endocrine therapy (ET) to attempt pregnancy did not increase the recurrence risk for breast cancer (BC) in young women with early hormone receptor-positive (HR+) BC.

Major finding: After a median follow-up of 41 months, 44 patients had BC and the incidence of BC events was not higher among patients who interrupted ET vs control individuals with BC from an external cohort who received treatment with different adjuvant endocrine strategies (hazard ratio 0.81; 95% CI 0.57-1.15). Pregnancy was reported by 368 patients and 317 patients had ≥1 live birth.

Study details: Findings are from a single-group trial including 516 premenopausal women aged ≤42 years with stage I, II, or III HR+ BC treated with ET for 18-30 months who discontinued ET to attempt pregnancy.

Disclosures: This study was supported by the ETOP IBCSG Partners Foundation and other sources. Some authors declared serving as consultants; receiving grants, contracts, or travel support; or having other ties with several sources.

Source: Partridge AH et al for the International Breast Cancer Study Group, and the POSITIVE Trial Collaborators. Interrupting endocrine therapy to attempt pregnancy after breast cancer. N Engl J Med. 2023;388(18):1645-1656 (May 4). Doi: 10.1056/NEJMoa2212856

Key clinical point: Temporarily discontinuing endocrine therapy (ET) to attempt pregnancy did not increase the recurrence risk for breast cancer (BC) in young women with early hormone receptor-positive (HR+) BC.

Major finding: After a median follow-up of 41 months, 44 patients had BC and the incidence of BC events was not higher among patients who interrupted ET vs control individuals with BC from an external cohort who received treatment with different adjuvant endocrine strategies (hazard ratio 0.81; 95% CI 0.57-1.15). Pregnancy was reported by 368 patients and 317 patients had ≥1 live birth.

Study details: Findings are from a single-group trial including 516 premenopausal women aged ≤42 years with stage I, II, or III HR+ BC treated with ET for 18-30 months who discontinued ET to attempt pregnancy.

Disclosures: This study was supported by the ETOP IBCSG Partners Foundation and other sources. Some authors declared serving as consultants; receiving grants, contracts, or travel support; or having other ties with several sources.

Source: Partridge AH et al for the International Breast Cancer Study Group, and the POSITIVE Trial Collaborators. Interrupting endocrine therapy to attempt pregnancy after breast cancer. N Engl J Med. 2023;388(18):1645-1656 (May 4). Doi: 10.1056/NEJMoa2212856

Key clinical point: Temporarily discontinuing endocrine therapy (ET) to attempt pregnancy did not increase the recurrence risk for breast cancer (BC) in young women with early hormone receptor-positive (HR+) BC.

Major finding: After a median follow-up of 41 months, 44 patients had BC and the incidence of BC events was not higher among patients who interrupted ET vs control individuals with BC from an external cohort who received treatment with different adjuvant endocrine strategies (hazard ratio 0.81; 95% CI 0.57-1.15). Pregnancy was reported by 368 patients and 317 patients had ≥1 live birth.

Study details: Findings are from a single-group trial including 516 premenopausal women aged ≤42 years with stage I, II, or III HR+ BC treated with ET for 18-30 months who discontinued ET to attempt pregnancy.

Disclosures: This study was supported by the ETOP IBCSG Partners Foundation and other sources. Some authors declared serving as consultants; receiving grants, contracts, or travel support; or having other ties with several sources.

Source: Partridge AH et al for the International Breast Cancer Study Group, and the POSITIVE Trial Collaborators. Interrupting endocrine therapy to attempt pregnancy after breast cancer. N Engl J Med. 2023;388(18):1645-1656 (May 4). Doi: 10.1056/NEJMoa2212856